Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRAER 1: Palupiprant + RT/CRT in Rectal Cancer
NCT03152370Phase 1Completed
- Sponsor
- Adlai Nortye
- Start
- May 2017
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of palupiprant in rectal cancer (2 arms), sponsored by Adlai Nortye. Primary endpoints: Maximum Tolerated Dose at 10 weeks, Dose Limiting Toxicities at 10 weeks and 2 more. Started May 2017; status: completed.
02
Drugs
palupiprant
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT03152370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03152370.